Qualitek Labs posted 33% YoY revenue growth in Q2 FY27, but a sharp rise in costs for new labs and higher debt interest pulled profit down by a third.
Qualitek Labs' Q2 FY27 revenue jumped 33% year-on-year to ₹72 crore, but profit fell 30% sequentially to ₹7 crore. The squeeze came from higher staff costs, other expenses, and a doubling of interest outgo to fund rapid lab expansion.
For Qualitek Labs, the September quarter was a story of growth delivered at a rising cost. The testing services firm continued its rapid expansion, adding labs to capture a market driven by stricter quality regulations. Yet this quarter, the bill for that ambition arrived ahead of the full payoff.
Revenue reached ₹72 crore, up 33% from a year earlier and 3% from the March quarter. Profit, however, fell to ₹7 crore, a 30% sequential drop even as it rose 40% year-on-year. The net profit margin compressed by 460 basis points to 9.7%.
Revenue & profit
Revenue (₹ Cr.)
Profit (₹ Cr.)
Revenue (₹ Cr.)
Profit (₹ Cr.)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 (Sep 2026) | PreviousQ4 FY26 (Mar 2026) |
|---|---|---|
| Revenue (₹ Cr.) | 72.0 | 70.0 |
| Profit (₹ Cr.) | 7.0 | 10.0 |
| Net Profit Margin (%) | 9.7 | 14.3 |
The profit squeeze came from costs rising faster than sales. According to reports from MCapital and Multibagg.ai, employee costs, other expenses, and finance charges all climbed sharply. Interest expense doubled year-on-year to ₹4 crore, a direct result of higher borrowings to fund capital work in progress (CWIP), which rose to nearly ₹70 crore.
This is the financial reality of a company in high-gear expansion. Qualitek added nine labs in the last 18 months, notes MCapital, which have a long-term revenue potential but currently incur losses during their gestation period. The company's debt-to-equity ratio stands at 0.72.
The growth thesis remains intact, anchored in regulatory tailwinds. Stricter quality mandates from bodies like BIS and FSSAI are expanding the addressable market for testing, which Minerva Capital Research estimates at ₹30,000 crore for Qualitek. Management has guided for revenue to double every two years until reaching a ₹500 crore topline.
Live Chart
· QLL
(BSE)
ISIN: INE0Q1R01012
Recent wins, like a ₹10.2 crore order from Indian Oil Corporation reported by ScanX, show the demand pipeline. The focus now is on filling the newly built capacity, a process that typically takes two to three years for labs to reach breakeven.
Key Points
The quarter lays bare the tension in Qualitek's model: high growth funded by debt, with profitability deferred until new capacity is utilized. The 460-basis-point sequential margin decline is a direct cost of that expansion.
For the thesis to hold, the company must successfully ramp up utilization in its new labs over the next several quarters to offset the rising interest and depreciation burden. Investors are betting that regulatory-driven demand will fill the capacity before leverage becomes a constraint. The next few quarters will test that timing.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.